- PhaseBio Pharmaceuticals Inc PHAS remains on track to complete the bentracimab biologics license application (BLA) filing around mid-2022 for bleeding risks associated with using ticagrelor antiplatelet drug.
- A pre-BLA filing meeting with FDA will take place in the coming months. Needham analyst says that based on prior FDA guidance, the interim results from the first ~100 patients of the REVERSE-IT trial could support accelerated approval.
- But the agency recommended that the initial ~100 patients should consist of an equal split between patients with uncontrolled/life-threatening bleeding and requiring urgent surgery/ invasive procedure.
- FDA stated that an imbalance would be a review issue.
- Though the interim results from the ph 3 REVERSE-IT trial of bentracimab met its co-primary endpoints, the interim evaluation mainly consisted of patients requiring urgent surgery/invasive procedures.
- Analyst Serge Belanger believes the interim REVERSE-IT results support approval and assumes a 2H 2023 launch.
- If FDA requires the full REVERSE-IT dataset, it could likely delay a potential approval by 12-16 mths or provide a partial approval (only for patients requiring urgent surgery/invasive procedures).
- PHAS estimates that in the U.S., 500,000 patients (~10% market share) undergo Brilinta therapy, which is expected to reach around 2 million (or 25-35% market share) by 2029 once the product loses patent in 2024.
- Assuming bentracimab pricing between $10k-$20k/dose, the addressable target market for the product represents an opportunity in the range of $750 million-$1.5 billion.
- Price Action: PHAS shares are trading at $1.24 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
